Clinical Trials Browser

Phase 2/3 × Nivolumab × Lymphoid × Clear all

NCT05595447 2025-03-12

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Phase 2/3 Recruiting

Hodgkin Disease, Recurrence

NCT03366272 2025-01-28

NIVEAU

Phase 2/3 Completed

Lymphoma, Non-Hodgkin